A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(33 sites)

United States

Saguaro Dermatology, Phoenix, Arizona

Encino Research Center, Encino, California

Clinical Science Institute, Santa Monica, California

Skin Care Research, Boca Raton, Florida

Center for Skin Science and Innovation, Fort Lauderdale, Florida

Ziaderm Research LLC, North Miami Beach, Florida

Clinical Trials Management, LLC, Tampa, Florida

DelRicht Research, Atlanta, Georgia

Southeast Research Specialist LLC, Douglasville, Georgia

The Indiana Clinical Trials Center, PC, Plainfield, Indiana

DS Research of Kentucky, Louisville, Kentucky

Martha Stewart, Mandeville, Louisiana

Clinical Trials Management, LLC, Metairie, Louisiana

DelRicht Research, New Orleans, Louisiana

Oakland Hills Dermatology, Auburn Hills, Michigan

MI Skin Innovations, Northville, Michigan

DelRicht Research, Wildwood, Missouri

JDR Dermatology Research LLC, Las Vegas, Nevada

Skin Cancer and Dermatology Institute, Reno, Nevada

Schweiger Dermatology, PC, Hackensack, New Jersey

Equity Medical LLC, The Bronx, New York

Optima Research - Boardman, Boardman, Ohio

Apex Clinical Research Center, LLC, Canton, Ohio

Apex Clinical Research Center, LLC, Mayfield Heights, Ohio

UPMC Department of Dermatology, Pittsburgh, Pennsylvania

Medical Univ of SC Department of Dermatology, Charleston, South Carolina

DelRicht Research, Mt. Pleasant, South Carolina

DelRicht Research, Smyrna, Tennessee

DelRicht Research, Prosper, Texas

Stryde Research-Epiphany Dermatology, Southlake, Texas

Dermatology Specialists of Spokane, Spokane, Washington

Canada

York Dermatology Clinical and Research Centre, Richmond Hill, Ontario

North York Research Inc., Toronto, Ontario